跳至主要内容
临床试验/NCT00700830
NCT00700830已完成不适用

Assessment of Safety and Efficacy of Levemir® (Insulin Detemir) Treatment for Insulin Naive Patients With Type 2 Diabetes Mellitus

Novo Nordisk A/S0 个研究点目标入组 1,976 人开始时间: 2008年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
1,976
主要终点
Assessment the incidence of the Serious Adverse Events including the major Hypoglycaemia.

研究概览

简要总结

This study is conducted in Africa. The aim of this study is to assess the safety and efficacy of Levemir® treatment for insulin naive patients with type 2 diabetes under normal clinical practice conditions in Algeria.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Informed consent obtained before any trial-related activities
  • Type 2 diabetes
  • HbA1c between 7-9%
  • Insulin naive
  • Inadequate control with oral antidiabetics therapy as judged by investigator

排除标准

  • Patients with type 1 diabetes
  • Hypersensitivity to Levemir® or to any of the excipients
  • Pregnancy, or desire of pregnancy within next 6 months
  • HbA1c greater than or equal to 9%
  • Known or suspected allergy to the trial product or to any of the excipients
  • Subjects who are unlikely to comply with protocol

研究组 & 干预措施

A

干预措施: insulin detemir (Drug)

结局指标

主要结局

Assessment the incidence of the Serious Adverse Events including the major Hypoglycaemia.

时间窗: During study

次要结局

  • FBG (Fasting Blood Glucose)(Monthly average for each month, and average of the past quarter)
  • Weight(after 12 weeks (3 months) AND after 24 weeks (6 months))
  • HbA1c(after 12 weeks (3 months) AND after 24 weeks (6 months))

研究者

申办方类型
Industry
责任方
Sponsor

相似试验